TIDES Europe: Oligonucleotide and Peptide Therapeutics is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

Lili Cui
Senior Formulation Scientist, Pharm Sci at Astrazeneca

Profile

Dr. Lili Cui obtained her first degree in Pharmaceutics from Shenyang Pharmaceutical University and her PhD in Pharmaceutical Science from King’s College London. During these periods, she has gained wide experience in drug delivery system design, drug formulation and in vitro & vivo delivery. She has developed a set of skills in nanomedicine (liposomes, polymeric nanoparticles, lipopolyplexes etc), nucleic acid delivery, peptide chemistry and cell biology. She started her career as a formulation scientist in Silence Therapeutics GmbH in 2015 where she has broadened her field in nucleic acid drug research and development (lipid nanoparticles, drug conjugate, novel lipids). She moved to AstraZeneca as a senior formulation scientist in 2017. Since then, she has been working on projects involving different nucleic acid-based modalities including mRNA, siRNA, pDNA, Crispr etc and different therapeutic area (oncology, liver, brain etc.). She has successfully delivered a few challenging nucleic acid and protein projects including building up formulation process capability to enable projects. She has been enthusiastic in science and technology and been active in getting involved in internal and external collaborations.

Lili Cui's Network

Agenda Sessions

  • Investigation of Lipid Nanoparticle Formulation Optimisations across Nucleic acid-based Modalities

    , 14:45

Speakers at this event